News - ALK translocation

20d

Ladarixin With Sotorasib in Advanced NSCLC (clinicaltrials.gov)

P1, N=40, Recruiting, NYU Langone Health | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027

20 days ago

Trial completion date • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation

Lumakras (sotorasib) • ladarixin (DF-2156A)

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) (clinicaltrials.gov)

P3, N=166, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)

ALK positive • ALK fusion • ALK translocation

Xalkori (crizotinib)

TRIM21 promotes K63-linked ubiquitination of ALKBH5 and suppresses cuproptosis via down-regulation of LIAS in esophageal squamous cell carcinoma. (PubMed, Commun Biol)

Combined treatment with an OGT inhibitor OSMI-1 and copper ionophore elesclomol eliminates tumor growth and remarkably enhances the sensitivity of tumor cells to cisplatin. Together, our study identifies TRIM21 Ubiquitinated-ALKBH5 as a critical gatekeeper to restrict cuproptosis, and such mechanism may contribute to tumor development and drug resistance in ESCC.

1 month ago

Journal

ALKBH5 (AlkB Homolog 5, RNA Demethylase) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • LIAS (Lipoic Acid Synthetase) • TRIM21 (Tripartite Motif Containing 21)

ALK translocation

cisplatin • elesclomol (STA-4783)

2ms

DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)

P1/2, N=7, Active, not recruiting, Sotio Biotech Inc. | Trial primary completion date: Oct 2027 --> Oct 2025

2 months ago

Trial primary completion date • First-in-human

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)

EGFR mutation • ALK translocation • BRCA mutation

cyclophosphamide • BOXR1030

2ms

KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)

P1, N=242, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)

EGFR mutation • ALK positive • ALK translocation • EGFR positive

Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)

2ms

NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

2 months ago

Enrollment open • Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK positive • ALK translocation

Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed

2ms

LIST: A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (clinicaltrials.gov)

P=N/A, N=535, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Apr 2025 | Trial primary completion date: Sep 2025 --> Apr 2025

2 months ago

Trial completion • Trial completion date • Trial primary completion date • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF mutation • ALK translocation

Opdivo (nivolumab)

2ms

Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy. (PubMed, Clin Transl Oncol)

Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.

2 months ago

Journal

ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)

TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK translocation

2ms

First description of ALK-positive NSCLC in a heart transplant patient (PubMed, Pneumologie)

ALK translocation is a rare driver mutation in non-small cell lung cancer. This is a case report about treatment of a heart transplanted patient with ALK-positive non-small cell lung cancer.

2 months ago

Journal

ALK (Anaplastic lymphoma kinase)

ALK positive • ALK translocation

3ms

GARNET: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=738, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jan 2027

3 months ago

Enrollment closed • Trial completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

EGFR mutation • MSI-H/dMMR • ALK translocation

Jemperli (dostarlimab-gxly)

3ms

MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression. (PubMed, Front Oncol)

Specifically, we highlight the modulatory roles of miRNA in cancer cell survival and proliferation (miR-28, miR-30b/c), invasion and metastasis (miR-218, miR-182), neoangiogenesis (miR-29c), metabolic reprogramming (miR-124), and therapy resistance (miR-378, miR-328, miR-1244). The broad implications of miRNAs in lung cancer underline their potential real-world utility, as these entities can function as biomarkers for prognosis/diagnosis and even future therapeutic targets or agents.

3 months ago

Review • Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MIR200C (MicroRNA 200c) • MIR30B (MicroRNA 30b) • NTRK (Neurotrophic receptor tyrosine kinase) • MIR182 (MicroRNA 182) • MIR328 (MicroRNA 328) • MIR218 (MicroRNA 218) • MIR22 (MicroRNA 22) • MIR33A (MicroRNA 33a)

KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • ALK translocation • NTRK fusion

3ms

QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=1538, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

3 months ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)